Advanced search    

Search: authors:"Carol L. Gaich"

6 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis

To assess the measurement properties of two single-item patient-reported outcome (PRO) measures that assessed the length of time (in minutes) and severity of morning joint stiffness (MJS) experienced each day. Data from two Phase 3, randomized placebo-controlled (and active-controlled [RA-BEAM]), clinical studies assessing the safety and efficacy of baricitinib in adults with...

Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis

To assess the measurement properties of two single-item patient-reported outcome (PRO) measures that assessed the length of time (in minutes) and severity of morning joint stiffness (MJS) experienced each day. Data from two Phase 3, randomized placebo-controlled (and active-controlled [RA-BEAM]), clinical studies assessing the safety and efficacy of baricitinib in adults with...

Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study

of Eli Lilly and Company; Natalie N. Boytsov, PhD is an employee and shareholder of Eli Lilly and Company; Carol L. Gaich, PharmD is an employee and shareholder of Eli Lilly and Company; Xiang Zhang

Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis

Elizabeth D. Bacci Amy M. DeLozier Chen-Yen Lin Carol L. Gaich Xiang Zhang Terence Rooney Stephanie de Bono Richard Hoffman Kathleen W. Wyrwich Background: To assess the reliability, validity, and

Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis

Elizabeth D. Bacci Amy M. DeLozier Chen-Yen Lin Carol L. Gaich Xiang Zhang Terence Rooney Stephanie de Bono Richard Hoffman Kathleen W. Wyrwich Background: To assess the reliability, validity, and

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and naïve to biological DMARDs. Patients were randomized 4:3:4 to MTX administered...